Ecor1 Capital, Llc Buys 73,953 Shares of Zymeworks Inc. (NYSE:ZYME) Stock

Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc purchased 73,953 shares of the stock in a transaction dated Wednesday, April 16th. The shares were acquired at an average cost of $11.16 per share, with a total value of $825,315.48. Following the acquisition, the director now directly owns 17,773,727 shares in the company, valued at $198,354,793.32. This represents a 0.42 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Friday, April 4th, Ecor1 Capital, Llc bought 196,438 shares of Zymeworks stock. The shares were acquired at an average cost of $11.17 per share, with a total value of $2,194,212.46.
• On Wednesday, April 2nd, Ecor1 Capital, Llc purchased 74,360 shares of Zymeworks stock. The stock was bought at an average price of $11.85 per share, for a total transaction of $881,166.00.
• On Monday, March 31st, Ecor1 Capital, Llc acquired 4,397 shares of Zymeworks stock. The shares were bought at an average price of $11.75 per share, with a total value of $51,664.75.
• On Wednesday, March 26th, Ecor1 Capital, Llc bought 43,848 shares of Zymeworks stock. The stock was bought at an average price of $12.24 per share, for a total transaction of $536,699.52.
• On Monday, March 24th, Ecor1 Capital, Llc purchased 22,689 shares of Zymeworks stock. The shares were bought at an average price of $13.08 per share, with a total value of $296,772.12.
• On Friday, March 21st, Ecor1 Capital, Llc acquired 31,033 shares of Zymeworks stock. The shares were purchased at an average cost of $12.78 per share, for a total transaction of $396,601.74.
• On Wednesday, March 19th, Ecor1 Capital, Llc bought 58,306 shares of Zymeworks stock. The stock was purchased at an average cost of $12.64 per share, with a total value of $736,987.84.
• On Monday, March 17th, Ecor1 Capital, Llc purchased 56,277 shares of Zymeworks stock. The shares were purchased at an average cost of $12.23 per share, for a total transaction of $688,267.71.
• On Thursday, March 13th, Ecor1 Capital, Llc acquired 468,356 shares of Zymeworks stock. The stock was purchased at an average cost of $12.48 per share, with a total value of $5,845,082.88.
• On Tuesday, March 11th, Ecor1 Capital, Llc bought 320,690 shares of Zymeworks stock. The shares were acquired at an average price of $11.49 per share, for a total transaction of $3,684,728.10.

Zymeworks Stock Performance

Zymeworks stock opened at $11.53 on Friday. The stock has a market capitalization of $802.22 million, a price-to-earnings ratio of -7.69 and a beta of 1.18. Zymeworks Inc. has a 52-week low of $7.97 and a 52-week high of $17.70. The stock’s 50 day moving average price is $12.38 and its two-hundred day moving average price is $13.52.

Institutional Investors Weigh In On Zymeworks

A number of large investors have recently bought and sold shares of the stock. FMR LLC raised its holdings in shares of Zymeworks by 84.2% during the third quarter. FMR LLC now owns 3,336 shares of the company’s stock valued at $42,000 after purchasing an additional 1,525 shares during the period. Stifel Financial Corp raised its stake in Zymeworks by 2.1% during the 3rd quarter. Stifel Financial Corp now owns 73,654 shares of the company’s stock worth $924,000 after buying an additional 1,540 shares during the period. State Street Corp raised its stake in Zymeworks by 6.1% during the 3rd quarter. State Street Corp now owns 1,171,777 shares of the company’s stock worth $14,706,000 after buying an additional 67,401 shares during the period. Jane Street Group LLC grew its stake in Zymeworks by 27.3% in the third quarter. Jane Street Group LLC now owns 80,326 shares of the company’s stock valued at $1,008,000 after acquiring an additional 17,205 shares during the period. Finally, Barclays PLC increased its holdings in shares of Zymeworks by 476.3% during the third quarter. Barclays PLC now owns 154,384 shares of the company’s stock valued at $1,937,000 after acquiring an additional 127,595 shares in the last quarter. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ZYME. Citigroup lifted their price target on shares of Zymeworks from $18.00 to $19.00 and gave the stock a “buy” rating in a report on Friday, March 7th. Lifesci Capital started coverage on Zymeworks in a report on Tuesday, March 11th. They set an “outperform” rating and a $30.00 target price on the stock. Finally, HC Wainwright increased their price target on Zymeworks from $12.00 to $13.00 and gave the company a “neutral” rating in a research note on Monday, March 10th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Zymeworks currently has an average rating of “Moderate Buy” and a consensus target price of $21.00.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.